Hinge Health raises $437.3 million in US IPO

Hinge Health raised $437.3 million in its U.S. IPO, pricing 13.7 million shares at $32 each, the high end of its $28-$32 marketed range. Despite the successful pricing, the IPO valuation is approximately 52% lower than the $6.2 billion valuation the company received in its 2021 Series E round. The digital health startup, which provides AI-driven musculoskeletal care, will list on the NYSE under the ticker "HNGE" with Morgan Stanley, Barclays Capital, and BofA Securities as lead underwriters.

Analysis

Hinge Health successfully executed its U.S. initial public offering, raising $437.3 million by pricing approximately 13.7 million shares at $32 each, the upper limit of its $28 to $32 marketed range. This strong pricing outcome for the digital health startup, which specializes in AI-driven musculoskeletal care, chronic pain management, and post-surgical rehabilitation, contrasts sharply with its prior private market valuation. The IPO valuation is nearly 52% lower than the $6.2 billion valuation Hinge Health achieved during its 2021 Series E funding round, indicating a significant market correction for late-stage growth companies transitioning to public markets. The company, founded in 2014, will list on the New York Stock Exchange under "HNGE", with Morgan Stanley, Barclays Capital, and BofA Securities serving as lead underwriters. The transaction occurs amidst a reported revival in the IPO market, partly attributed to de-escalating U.S.-China trade tensions, although Hinge Health's valuation reset underscores a more cautious investor sentiment compared to the peak funding environment of 2021.

Key Decisions for Investors

• Investors should critically evaluate Hinge Health's post-IPO growth trajectory and profitability potential, considering the substantial valuation haircut from its 2021 private funding round despite pricing at the high end of its IPO range.
• The significantly lower IPO valuation compared to its previous private market peak might present a revised entry point for public investors, but it also highlights the valuation pressures facing digital health companies and the broader tech sector in the current market.
• Monitor the early trading performance of 'HNGE' and peer valuations within the digital health and AI-enabled healthcare space to assess market reception and the sustainability of its public valuation.
• Consider that while the IPO market shows signs of revival, Hinge Health's experience suggests that companies coming to market may still face considerable valuation adjustments from prior, more exuberant, private funding levels.